JAMA
Original Investigation
April 8, 2024
Steven E.ÌýNissen, MD; Kathy Wolski, MPH; Gerald F.ÌýWatts, MD, DSc; Michael J.ÌýKoren, MD; Henry Fok, MBBS, PhD; Stephen J.ÌýNicholls, MBBS, PhD; David A.ÌýRider, PhD; Leslie Cho, MD; Steven Romano, MD; Carrie Melgaard, MS; Curtis Rambaran, MBBS, MD
JAMA. 2024; 331(18):1534-1543. 10.1001/jama.2024.4504
This phase 1 randomized study assesses the safety and tolerability of zerlasiran, a short interfering RNA targeting hepatic synthesis of apolipoprotein(a), and its effects on serum concentrations of lipoprotein(a), in healthy participants and patients with stable atherosclerotic cardiovascular disease.
JAMA Cardiology
Comment & Response
October 1, 2017
Michael J.ÌýKoren, MD, CPI; Marc S.ÌýSabatine, MD, MPH
JAMA Cardiol. 2017; 2(10):1169-1169. 10.1001/jamacardio.2017.2734
JAMA Cardiology
Original Investigation
June 1, 2017
Michael J.ÌýKoren, MD; Marc S.ÌýSabatine, MD, MPH; Robert P.ÌýGiugliano, MD, SM; Gisle Langslet, MD; Stephen D.ÌýWiviott, MD; Helina Kassahun, MD; Andrea Ruzza, MD, PhD; Yuhui Ma, PhD; Ransi Somaratne, MD; Frederick J.ÌýRaal, MBBCh, MMED, PhD
open access
JAMA Cardiol. 2017; 2(6):598-607. 10.1001/jamacardio.2017.0747
This observational extension of the OSLER-1 randomized clinical trial determines whether low-density lipoprotein cholesterol level reductions with evolocumab persist across different patient populations.